Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse by Sali, Arpana et al.
Glucocorticoid-Treated Mice Are an Inappropriate
Positive Control for Long-Term Preclinical Studies in the
mdx Mouse
Arpana Sali
1., Alfredo D. Guerron
1., Heather Gordish-Dressman
1, Christopher F. Spurney
3,
Micaela Iantorno
1, Eric P. Hoffman
1,2, Kanneboyina Nagaraju
1,2*
1Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, United States of America, 2Department of Integrative Systems Biology,
George Washington University School of Medicine and Health Sciences, Washington DC, United States of America, 3Division of Cardiology, Children’s National Medical
Center, Washington DC, United States of America
Abstract
Background: Dmd
mdx (mdx) mice are used as a genetic and biochemical model of dystrophin deficiency. The long-term
consequences of glucocorticoid (GC) treatment on dystrophin-deficient skeletal and heart muscle are not yet known. Here
we used systematic phenotyping to assess the long-term consequences of GC treatment in mdx mice. Our investigation
addressed not only the effects of GC on the disease phenotype but also the question of whether GCs can be used as a
positive control for preclinical drug evaluations.
Methods and Findings: We performed nine pre-clinical efficacy trials (treated N=129, untreated N=106) of different
durations in 9-to-50-week-old dystrophic mdx mice over a 3-year time period using standardized methods. In all these trials,
we used either 1 mg/kg body weight of prednisone or 5 mg/kg body weight of prednisolone as positive controls to
compare the efficacy of various test drugs. Data from untreated controls and GC-treated mice in the various trials have been
pooled and analyzed to assess the effects of GCs on dystrophin-deficient skeletal and cardiac muscles of mdx mice. Our
results indicate that continuous GC treatment results in early (e.g., at 50 days) improvements in normalized parameters such
as grip strength, motor coordination and maximal in vitro force contractions on isolated EDL muscle, but these initial
benefits are followed by a progressive loss of muscle strength after 100 days. We also found a significant increase in heart
fibrosis that is reflected in a significant deterioration in cardiac systolic function after 100 days of treatment.
Conclusion: Continuous administration of prednisone to mdx mice initially improves skeletal muscle strength, but further
therapy result in deterioration of muscle strength and cardiac function associated with enhanced cardiac fibrosis. These
results suggest that GCs may not serve as an appropriate positive control for long-term mdx mouse preclinical trials.
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Introduction
Glucocorticoids (GCs) are among the most widely prescribed
drugs because of their anti-inflammatory and immunosuppressant
properties. Randomized controlled studies have indicated that GC
therapy in Duchenne muscular dystrophy (DMD) improves
muscle strength, ambulation, and respiratory function and
decreases scoliosis in short-term studies [1,2]. GC treatment
elicited significant improvements in whole-body strength as well as
measurable incremental increases in running endurance in mdx
mice. This treatment also appeared to protect mdx mice from the
stressful effects of continuous running, as determined by strength
and muscle fiber diameter [3].
However, the use of GCs in DMD remains controversial, in part
because of their significant side effects, including osteoporosis,
growth retardation, and immune suppression. Furthermore, the
beneficial effects of GCs may depend on pathways other than
those associated with their well-documented anti-inflammatory
properties. Studies of other immunosuppressive drugs, such as
azathioprine, have shown decreases in inflammatory infiltrates in
DMD skeletal muscle similar to those produced by prednisone, but
these drugs did not show the improved muscle strength associated
with prednisone [4]. Golumbek et al. have also demonstrated that
mdx mice deficient in mature T and B lymphocytes do not show
any functional improvements in disease phenotype [5]. These
studies suggest that some of the therapeutic effects of GCs are
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unclear when the beneficial effects of GCs wane and further
therapy leads to adverse effects in dystrophin deficiency.
The purpose of the current study was to a) comprehensively
analyze the effects of chronic continuous GC administration on
dystrophin-deficient mdx mice and b) evaluate whether GCs can be
used as positive controls in preclinical drug efficacy trials in the
mdx mouse model. In this study, we used a wide variety of
behavioral, functional, histological, biochemical, imaging, and
molecular assays to comprehensively assess the effects of GCs
administered for 50, 100, or 180 days to the mdx mice. We found
that treatment with GCs resulted in weight loss and an initial,
partial improvement in grip strength but a subsequent progressive
loss of strength, catabolic effects, and deterioration in functional,
histological, and biochemical measures in dystrophin-deficient
skeletal and cardiac muscle.
Methods
Animal Care
All mice were handled according to local Institutional Animal
Care and Use Committee (IACUC) guidelines. Generally, 8- to
10-week-old female C57BL/10ScSn-Dmd
mdx/J (mdx) mice weigh-
ing approximately 20–25 g were purchased from The Jackson
Laboratory (Bar Harbor, ME). All mice were housed in an
individually ventilated cage system with a 12-h light-dark cycle
and received standard mouse chow (Harlan Teklad) and water ad
libitum. All mice were allowed to rest for at least 7 days in the
facility before acclimatizing them on the instruments and taking
baseline readings for behavioral assays.
Study Design
We tested the efficacy of nine drugs over a period of 3 years
(July 2006 to July 2009) in the mdx (Duchenne muscular
dystrophy) mouse model. In each trial, we used a prednisone
arm to assess and compare the efficacy of the test drugs to that of
current standard clinical therapy. In order to address the issue of
the efficacy of prednisone in mdx mice, we pooled the data from
the prednisone-treated groups from all nine trials (n=129) and
compared the aggregate results to those for untreated controls
(n=106) after 50, 100, and 180 days of chronic administration of
prednisone. We would like to note that we have used prednisone as
well as prednisolone preparations and administered the drugs by
various routes (subcutaneous pellets, oral chow, and daily syrup).
Five trials used subcutaneous prednisone, three used prednisolone
chow, and one used prednisolone syrup. Since all of these modes of
prednisone/prednisolone administration resulted in similar weight
loss, we have combined them into one group and designated this
aggregate as the GC-treated group.
Drug Treatment
mdx mice were treated with GC in three different ways: 1)
Prednisone (Innovative America, Inc) was administered in the form
of slow-release subcutaneous pellets at 1 mg/kg/day; for studies
with a 180-day treatment period, two pellets were used per mouse,
with the second pellet being implanted after 3 months. 2)
Prednisolone at 5 mg/kg/day in syrup form was given orally once
per day. 3) Prednisolone (5mg/kg body weight) was administered in
a custom-made mouse chow research diet (Harlan Teklad) for 50,
100, or 180 days. Actual diet consumption of the drug-treated
group varied in 100- and 180-day treatment periods, and the
average daily consumption of prednisolone was 3.77–4.15 mg/day.
Behavioral and Functional Assessments
In order to unmask the disease phenotype, we subjected mdx
mice to treadmill exercise (a 30-min run on a horizontal treadmill
at 12 m/min, twice a week) as described previously [6]. Grip
strength, motor coordination (Rota-Rod), and open field activity
were assessed as detailed previously [6,7,8]. For echocardiography,
mice were anesthetized with 1–2% isoflurane in 100% oxygen,
and scanning was performed over 20 min using a high-frequency
ultrasound probe (RMZ 702a, Vevo 770, VisualSonics, Toronto,
Canada) as previously described [8]. Qualitative and quantitative
measurements were made offline using analytic software (Visual-
Sonics, Toronto, Canada). For in vitro muscle force testing, the
extensor digitorum longus (EDL) muscle from the right hindlimb
was removed from an anesthetized mouse and placed vertically in
a bath containing buffered mammalian Ringer solution (25
0C) and
bubbled with 95% O2–5% CO2. The distal tendon of the muscle
was tied securely to the lever arm of a servomotor/force
transducer (model 305B, Aurora Scientific), and the proximal
tendon was fixed to a stationary post in the bath. The muscle was
stimulated between two stainless steel plate electrodes. At optimal
muscle length, the force developed was measured during trains of
stimulation (300 ms) with increasing frequencies until the highest
plateau was achieved. The force generated to obtain the highest
plateau was established as the maximal force generated by the
muscle and expressed in milliNewtons (mN). The specific force,
expressed as kN/m
2, was obtained by dividing the maximal force
by the physiologic cross-sectional area of muscle. The physiologic
cross-sectional area was calculated by dividing the muscle mass by
the fiber length and density (1.056 kg/m
3) of the muscle tissue.
The fiber length was established as 0.71 of the length of the EDL.
Histology
Mice in each of the nine drug trials were sacrificed at different
ages, and the skeletal muscles were collected for hematoxylin and
eosin staining (H&E). The muscles were stored in formalin for
H&E staining. Serum was also acquired from these mice for use in
estimating creatine kinase levels. For H&E staining, the gastroc-
nemius muscle was stained as previously described [6]. For
quantification, five non-overlapping representative fields of the
stained tissue sections were imaged under a light microscope
(20X), and a digital image for each field was obtained using
computer software (Olympus America Inc., Center Valley, PA).
The digital images were loaded into Image J (NIH) with an
additional plug-in to count cells. In brief, the total fibers present,
total fibers with central nuclei, regenerating fibers (basophilic
fibers), degenerating fibers, and inflammation (defined as an
interstitial group of 10 smaller inflammatory cells with dark-blue
nuclei in one high-power field) were assessed. Quantitative
procedures were performed as detailed previously [6].
Quantification of Fibrosis
Paraffin sections were stained with Sirius Red stain (Sigma-
Aldrich, St. Louis, MO) and counter-stained with hematoxylin to
visualize nuclei. The tissue was imaged under a light microscope
using a 4X objective, and a digital image was obtained using
computer software (Olympus C.A.S.T. Stereology System, Olym-
pus America Inc., Center Valley, PA). The digital images were
processed using Image J (NIH), with an additional threshold color
plug-in to process .jpeg images. The percentage of the fibrotic area
corresponding to the area stained in red was compared to the total
area of the tissue section, and the results were expressed as %
fibrosis.
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Multiple traits were analyzed in the mdx mice, comparing the
levels in mice treated with GC to those in control (non-drug-
treated) mice. All traits not meeting the assumption of normality
were transformed using either a log (total distance, CK level, and
cardiac fibrosis) or square root (EDL weight) transformation.
Those traits for which transformation did not produce the desired
normality (Rotarod, rest time, and vertical activity) were
subsequently analyzed using alternative methods such as quantile
(or median) regression models with age, trial, and weight
covariates. The mean levels of each trait at baseline were
compared in the treated and untreated mice to determine whether
any differences in the groups might have existed at the outset of
the study. Comparisons of normally distributed and transformed
traits were made using ANCOVA models with age, trial, and
weight covariates. Comparisons of non-normally distributed traits
were made using quantile (or median) regression models with age,
trial, and weight covariates. Comparisons of mean levels of each
trait were also tested at 50, 100, and 180 days of prednisone
treatment. The same models were used as in the baseline
measures, with the addition of a covariate describing the actual
number of days each mouse was on GC treatment. Untreated
mice were assigned the same number of actual days on GC as their
analogous treated group in order to adequately model both
treatment groups.
Results
Effect on Body Weight
Body weight (BW) decreased significantly in mice that received
GCs for 50, 100, or 180 days, as compared to untreated mdx mice;
the rate of BW gain in the GC-treated mice was significantly lower
than that in the untreated mdx mice (Figure 1A). The loss in BW
gain occurred within 50 days of treatment, and the change in the
rate of gain after 50 days was not significant between the treated
and untreated groups (Figure 1B). There were no significant
differences in the weights of the gastrocnemius and soleus muscles
at 50, 100, and 180 days, but the EDL muscle weight was
significantly decreased at 100 days in the GC-treated mice
(p,0.002; Table 3). The spleen weights of the GC-treated mice
showed a significant decrease at 100 days (p,0.05), but not at 50
or 180 days of treatment (Table 1). In contrast to the results for
skeletal muscle, there was a significant and consistent increase in
the heart weight of the GC-treated mice at 100 (p,0.001) and 180
(p=0.001) days (Table 1).
Effect on Grip Strength, Motor Coordination, and
Behavioral Measurements
There were no significant differences between the groups in
terms of the maximal forelimb or hindlimb grip strength at 50,
100, or 180 days. Both groups showed a decline in grip strength
over time (Table 2). However, the treated mice had significantly
higher normalized forelimb strength than did controls at 50
(p,0.05) and 100 (p,0.05) days, but not at 180 days (Figure 2A).
Normalized hindlimb grip strength did not differ significantly
between the groups (Figure 2B). There was a significant increase in
motor coordination performance in the treated groups at 50
(p,0.05) and 100 (p,0.01) days, but not at 180 days, in terms of
the latency to-fall normalized to body weight on the Rotarod
(Figure 2C). Open-field behavioral activity parameters such as
horizontal activity, total distance and rest time were not
significantly different between the groups, with the exception of
vertical activity, which was significantly higher in the GC-treated
mice at the 180-day time point (p,0.04;Table 2). However,
normalization of behavioral parameters to body weight also
resulted in significantly improved behavioral activity in the treated
groups at 50 days and 100 days, and many of these benefits
vanished by 180 days.
Effect on Heart Function and Fibrosis
Since cardiomyopathy develops at a later age in mdx mice, we
did not measure heart function at 50 days. We did not see
significant differences in the left ventricular ejection fraction and
shortening fraction measures at 100 days of treatment, but these
measures were significantly reduced in the GC-treated group at
180 days (p,0.01and p,0.001, respectively; Figure 3A, B). The
rate of decline in cardiac function in the GC-treated group was
much more rapid than that in the untreated group between 100
and 180 days of treatment. Evaluation of normalized left
ventricular volumes indicated that at 100 days, GC-treated mice
had significantly (p=0.016) larger normalized volumes
(2.4660.17) than did untreated (1.8960.16) mice, indicative of a
dilated cardiomyopathy. There was a significant increase in
cardiac fibrosis in the GC-treated group at both 100 (p,0.05) and
180 (p,0.01) days (Figure 3C).
Figure 1. Effect of treatments on body weight. (A) mdx mice received no treatment (N=84, 83, and 44) or GC treatment (N=92, 89, and 38) for
50, 100, or 180 days, respectively, *** p=,0.001. (B) Comparison of the % rate change in body weight of untreated and GC-treated mice at 50, 100,
and 180 days. The rate at which body weight changed was established in the first 50 days, when the change occurred in the untreated mice at a
much faster rate (,0.0001). The rate remained greater than that for the treated mice, but the change over time was the same for both groups. Error
bars indicate mean+/- SEM.
doi:10.1371/journal.pone.0034204.g001
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Since behavioral measures are subject to the animal’s volitional
efforts, we have measured in vitro force contractions on isolated
EDL muscle. In comparison to the EDL muscle from the
untreated mice, the maximum force (mN) in the EDL muscle
from the GC-treated mice was significantly higher at 100 days
(p,0.3), but this effect was eventually lost at 180 days (p=0.18).
GC treatment reduced the EDL muscle mass. The specific force
(KN/m
2) did not differ between the two groups at either 100 or
180 days (Table 3).
Effect on Skeletal Muscle Histology
Examination of H&E-stained sections of gastrocnemius muscle
from the GC-treated mice showed a significant decrease in the
numberofinflammatorycellsat100(p,0.01)and180(p,0.05)days
and in the number of total central nuclei (p,0.05) and number of
Table 1. Weight of muscles and spleen in untreated and GC-treated mice.
Time
(days) Tissues GC treated group Untreated group
p-value for treatment
group
N
Mean ± SEM
Weight (mg) N
Mean ± SEM
Weight (mg)
,50 Gastrocnemius 11 135.662.7 9 138.963.0 0.424
Soleus 11 10.260.4 9 9.660.4 0.304
Heart 11 106.664.7 9 101.665.2 0.486
Spleen weight 11 82.363.2 9 83.963.5 0.737
,100 Gastrocnemius 45 143.462.1 41 144.662.2 0.734
Soleus 45 9.960.2 41 9.760.2 0.596
Heart 45 120.862.3 41 104.862.4 ,0.001
Spleen 45 87.361.9 41 93.562.0 0.047
,180 Gastrocnemius 36 130.962.3 37 136.562.2 0.199
Soleus 36 9.260.2 37 8.960.2 0.468
Heart 35 120.663.2 38 103.463.1 0.001
Spleen 36 92.263.3 38 90.563.2 0.742
doi:10.1371/journal.pone.0034204.t001
Figure 2. Effect of treatments on normalized grip strength. (A) Forelimb grip strength and (B) Hindlimb grip strength were measured using a
grid at 50, 100, and 180 days of age. (C) Latency to fall normalized to body weight was measured using a rotating rod. mdx mice received no
treatment (N=84, 82, and 44) or GC treatment (N=92, 87, and 38) for 50, 100, or 180 days, respectively. Error bars indicate mean +/- SEM. ** p =
,0.01 and * p = ,0.05.
doi:10.1371/journal.pone.0034204.g002
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Time
(days) Measurement GC treated group Untreated group
N Mean ± SEM N Mean ± SEM
,50 GSM – forelimb (KGF) 92 0.11860.002 84 0.11660.002
GSM – hindlimb (KGF) 92 0.18360.003 84 0.19260.003
Normalized GSM – forelimb (KGF/KG) 92 4.960.1 84 4.560.1#
Normalized GSM – hindlimb (KGF/KG) 92 7.560.1 84 7.660.1
Rotarod* (sec) 92 11765 84 11365
Normalized Rotarod* (sec/kg) 92 50276300 84 40646314#
Horizontal activity (units) 74 1357641 72 1379642
Normalized horizontal activity (units/kg) 74 5824361629 72 5304861663#
Total distance** (cm) 74 5.660.1 72 5.660.1
Normalized total distance** (cm/kg) 74 9.460.1 72 9.360.1
Rest time * (sec) 74 565.061.4 72 564.261.5
Normalized Rest time * (sec/kg) 74 238416200 72 219736202#
Vertical activity * (units) 74 33.963.1 72 29.763.2
Normalized vertical activity * (units/kg) 74 14256111 72 11626116
,100 GSM – forelimb (KGF) 87 0.10260.002 82 0.10360.002
GSM – hindlimb (KGF) 87 0.18560.003 83 0.19460.003
Normalized GSM – forelimb (KGF/KG) 87 4.260.1 82 3.960.1#
Normalized GSM – hindlimb (KGF/KG) 87 7.560.1 83 7.460.1
Rotarod* (sec) 87 10266 82 11166
Normalized Rotarod* (sec/kg) 87 50606281 82 39586294#
Horizontal activity (units) 87 1661654 82 1597656
Normalized horizontal activity (units/kg) 87 6710261969 82 6055462028#
Total distance** (cm) 87 6.060.1 82 6.060.1
Normalized total distance** (cm/kg) 87 9.760.0 82 9.560.1#
Rest time * (sec) 87 556.163.0 82 564.463.1
Normalized Rest time * (sec/kg) 87 230476368 82 208546377#
Vertical activity * (units) 87 38.365.1 82 35.165.4
Normalized vertical activity * (units/kg) 87 14096112 82 15926116
,180 GSM – forelimb (KGF) 38 0.09760.002 44 0.10260.002
GSM – hindlimb (KGF) 38 0.18060.003 44 0.18560.003
Normalized GSM – forelimb (KGF/KG) 38 4.060.1 44 3.760.1
Normalized GSM – hindlimb (KGF/KG) 38 7.160.1 43 6.960.1
Rotarod* (sec) 38 95614 44 103613
Normalized Rotarod* (sec/kg) 38 36766607 44 37866559
Horizontal activity (units) 38 1358663 44 1311657
Normalized horizontal activity (units/kg) 38 5192962062 44 5029261916
Total distance** (cm) 38 5.760.1 44 5.760.1
Normalized total distance** (cm/kg) 38 9.460.1 44 9.360.1
Rest time * (sec) 38 562.564.6 44 563.764.0
Normalized Rest time * (sec/kg) 38 233286369 44 199236349#
Vertical activity * (units) 38 28.562.5 44 20.862.2#
Normalized vertical activity * (units/kg) 38 9836107 44 7856103
*Analyzed using quantile regression due to non-normality
**Data transformed to conform to normality (total distance, move time, CK level, and cardiac fibrosis were log transformed; EDL weight was square transformed)
#Significantly different p values for treatment groups
doi:10.1371/journal.pone.0034204.t002
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180 days(p,0.05),whencomparedtotheuntreatedmice(Figure4A-
C).
Discussion
In this study, we have taken a comprehensive approach to
evaluating the effects of chronic administration of GC on the
disease phenotype in mdx mice. Our data indicate that continuous
administration of GCs significantly improves the disease pheno-
type (normalized behavioral parameters) early in the disease but
that these beneficial effects are eventually lost with continued
treatment. In addition, our data indicate that prolonged GC
administration significantly decreases heart function and increases
heart fibrosis, indicating that prolonged GC treatment is
detrimental to dystrophic heart and skeletal muscle and further
suggesting that these drugs may not be appropriate positive
therapeutic controls for long-term preclinical drug testing in this
mouse model.
Since body weight is a simple measure of the overall drug effect
on the mouse phenotype, we measured body weight and found a
significant decrease in the body weight of mdx mice. GCs are
known to induce catabolic effects in skeletal muscle by activating
the ubiquitin-proteosome pathway. It has previously been
demonstrated that muscle-specific E3 ligases (Atrogin-1/MAFbx
and Murf1) are up-regulated in response to GC administration in
skeletal muscle [9].
A decrease in body weight and reduction in weight gain with
GC treatment are well-documented in the literature: For example,
Keeling et al. performed an 84-week trial of twice-weekly oral
prednisolone and followed the survival of the treated mdx mice
through 104 weeks of age. They found that the treated mice
Figure 3. Effect of treatments on cardiac function and fibrosis. (A) Ejection fraction (%) and (B) shortening fraction (%) were assessed by
echocardiography in mice who received no treatment (N=30, 21) or GC treatment (N=25, 19) for 100 or 180 days, respectively. (C) Sirius Red staining
of formalin-fixed heart sections was used to estimate collagen content. mdx mice received no treatment (N=12, 13) or GC treatment (N=11, 14) for
100 or 180 days, respectively. Error bars indicate mean +/- SEM. **p =,0.01 and ***p =,0.001.
doi:10.1371/journal.pone.0034204.g003
Table 3. Muscle force at 100 and 180 days in untreated and GC-treated mice.
Time
(days) Measurement GC treated group Untreated group
p-value for
treatment group
N Mean ± SEM N Mean ± SEM
,100 Maximum force (mN) 20 319612 20 260612 0.027
Specific force (kN/m
2)2 0 1 5 8 652 0 1 5 7 65 0.925
EDL muscle mass (mg) 20 13.160.3 20 14.760.3 0.002
,180 Maximum force (mN) 6 374622 6 418622 0.182
Specific force (kN/m
2) 6 192612 6 200612 0.640
EDL muscle mass (mg) 6 12.860.3 6 13.660.3 0.072
doi:10.1371/journal.pone.0034204.t003
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of body weight than did the untreated mdx mice [10]. Similar
observations were also made by Lefaucheur et al. [11]. However,
Keeling’s study did not show any significant improvement in grip
strength between 3 and 10 weeks under non-exercise conditions
[10]. Granchilli et al. found a 24% increase in strength
(normalized to body weight) in mdx mice that were treated with
1mg/kg prednisone for 6 weeks and subjected to forced treadmill
exercise (20cm/sec) for 30 min twice a week [12]. These authors
found that higher doses of prednisone (5, 10, and 20mg/kg) were
detrimental to strength. This result is consistent with our finding
that 50-day treatment with 1mg/kg of GCs significantly improved
normalized forelimb grip strength and that the rate of decline was
slower than that in untreated mice, suggesting the beneficial effects
of drug treatment persist up to 100 days but become non-
significant by 180 days. Granchelli and colleagues reported
greater strength, decreased fatigue, and increased muscle fiber
diameters in treated mice, suggesting a protective effect of GCs
[12]. In 2007, Golumbek et al. similarly described an improved
performance per body weight and in running speed in mdx mice
receiving GC treatment, but they also reported an incremental
increase in the frequency of calcifications [5]. Another study by
Yang et al. examined the effect on diaphragm function of a 6-week
(2.25 mg/kg) treatment with methylprednisolone [13]. They
found a slight improvement in the contractile properties of the
treated mice; however, they did not look at skeletal muscle
function.
The present study has shown that prolonged steroid use leads to
decreased cardiac systolic function and increased cardiac fibrosis
in mdx mice. These results are in agreement with those of Bauer et
al., who found that 1.5 mg/kg/day prednisolone delivered via
drinking water over 8 weeks in 4-month-old mdx mice resulted in
increased left ventricular dilatation, decreased diastolic function,
and increased cardiac fibrosis [14]. Previous work from our
laboratory has also demonstrated significantly decreased cardiac
function and increased cardiac fibrosis in a subcutaneous,
continuous prednisone delivery protocol at a dose of 1 mg/kg/
day [8]. Skrabek and Anderson treated 2- to 3-month-old mdx
mice daily with intraperitoneal prednisone (1 mg/kg) or deflaza-
cort (0.65 and 1.2 mg/kg) and found significantly decreased
fibrosis only in the high-dose deflazacort-treated mdx mice. The
low-dose deflazacort and prednisone (equipotent with the high-
dose deflazacort) did not show any significant differences from
untreated mice. Thus, prednisone treatment did not increase
cardiac fibrosis in this study, in part because of the short duration
of the study [15]. However, an earlier study by Marques et al.
found a decrease in cardiac fibrosis in 6-month-old mdx mice
treated with 1.2 mg/kg of deflazacort in the drinking water for
15 months [16]. These results are in direct contrast to our current
study and the others previously mentioned. The differences could
be due to the difference in drug (deflazacort vs prednisone/
prednisolone), sex, age, and duration of drug administration. It
also appears that long-term administration of deflazacort has
negative consequences on heart function in the delta-sarcoglycan-
deficient cardiomyopathic hamster, suggesting that careful studies
are needed to confirm and validate the previously reported
beneficial effects of these drugs in mdx mice [17]. It is also worth
noting that most animal studies use more-continuous delivery
methods (drinking water, chow, subcutaneous pellet) than do
clinical studies, and this continuous administration may be more
deleterious than the single-dose therapies used clinically in human
patients. Recent evidence has shown that pulsed steroids can
resynchronize cell cycling and cytokine signaling, leading to
decreased inflammation after injury in an asthma cell culture
model [18]. Perhaps an optimal GC dosing schedule could help
minimize inflammation, whereas other GC dosing schedule would
Figure 4. Hematoxylin and eosin (H & E) evaluation of skeletal muscle. H&E staining was carried out to assess the effect of treatment on
inflammation (A), central nucleation (B), and fibers with central nucleation (C). Inflammatory cells were quantified in five non-overlapping fields in
gastrocnemius muscle. mdx mice received no treatment (N=4, 15, and 15) or GC treatment (N=4, 18, and 16) for 50, 100, or 180 days, respectively.
Error bars indicate mean+/- SEM. * p = ,0.05 and ** p = ,0.01.
doi:10.1371/journal.pone.0034204.g004
Effect of Glucocorticoids in Dystrophin Deficiency
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34204increase it. Further studies in animal models should more closely
replicate clinical dosing schedules to allow us to better assess any
deleterious effects.
We also assessed the overall behavioral activity of the mice using
an open-field Digiscan apparatus and found that the animals
adapted to the Digiscan apparatus over a period of time and
generally performed better with time than they did at the initial
time point. A comparison of the treatment groups clearly indicated
that the GC-treated group generally showed higher behavioral
activity measures (grip strength, Rotarod performance, open-field
activity) when the GC was normalized to body weight in early
stages of the treatment. The beneficial effects are clearly related to
the loss of body weight that occurs upon GC treatment. Many of
beneficial effects are abolished by 180 days, indicating that even
the normalized beneficial effects are transient. It is likely that the
side effects of GC overtake the beneficial effects after prolonged
GC treatment in dystrophin-deficient mice.
Taken together, these data point to beneficial effects of GCs
early in the period of administration but also to deleterious effects
associated with chronic administration. It is generally accepted
that therapy with corticosteroids improves the muscle strength of
patients and benefits their ambulation, scoliosis, and respiratory
function. The treatment has only engendered problems with
weight gain as the principal side effect. Results similar to ours have
been reported by Granchelli et al, who found that a dose of 1 mg/
kg/d of prednisone improved strength in mdx mice by 24%,
whereas higher doses ranging from 5 to 20 mg/kg were
deleterious [12].
Our findings in mice point out clear differences from the human
experience with GCs in DMD patients. Based on the recommen-
dations of an international workshop in 2004, daily steroid therapy
has become the ‘‘gold standard’’ treatment in DMD patients [19].
These recommendations had been based on many studies that
showed the benefits of steroids on skeletal and respiratory muscle
function [20,21,22,23]. Studies then began to focus on the cardiac
effects. Silversides et al. showed that only 5% of patients treated
with deflazacort for 3 or more years had a significantly decreased
ejection fraction, as compared to 58% of untreated patients [24].
They also found a correlation between preservation of cardiac
function and improvement in pulmonary and skeletal muscle
function. Markham et al. found that steroid-naı ¨ve subjects
10 years old or younger were 4.4 times more likely to have
decreased cardiac function, and those older than 10 years were
15.2 times more likely to have decreased function [25]. Of
particular interest is the fact that patients who had received
steroids but were no longer taking them showed normal cardiac
function and no differences from patients who continued to receive
steroids. Biggar et al. reported that 59% of their untreated DMD
patients developed decreased cardiac function by 18 years of age,
as compared to 10% of steroid-treated patients [23]. Houde et al.
found that deflazacort treatment preserved cardiac function in
DMD patients over an 8-year follow-up study [26]. Treated
patients had improved systolic function and a decreased incidence
of dilated cardiomyopathy (32% vs. 58%) when compared to
younger untreated patients. Markham et al. reported that 93% of
steroid-treated DMD children maintained normal cardiac func-
tion, as compared to only 53% of untreated children [25]. These
studies support the idea that DMD patients treated with steroids
prior to the onset of cardiac dysfunction show a slower progression
of heart disease. The study by Markham et al. also questioned
whether there is an early therapeutic window for obtaining the
beneficial effects of steroid therapy in cardiac muscle [25].
However, questions still remain regarding the best type of steroid
to use and the optimal age of therapy initiation, dosing schedule,
and duration of therapy. Further studies addressing these questions
and utilizing improved cardiac outcome measures are clearly
needed.
The significant increase in collagen deposition that we saw in
the GC-treated group suggests that long-term treatment with GCs
is detrimental to heart function, not only in the mdx model but in
other models of muscular dystrophy in which heart damage is
evident in the early stages [27]. The amount of collagen observed
in the heart was significantly higher in the GC-treated group than
in the control group at either 100 or 180 days, and similar results
were found in the EDL at 100 days (data not shown). However,
Hartel in 2001 reported an advantage of prednisone in reducing
TGF-b and hydroxyproline levels in the diaphragm, suggesting a
potential involvement in the genesis of fibrosis [28]. In contrast, no
significant differences were found in CK. In 1991, Weller reported
that methylprednisolone failed to significantly influence the time
course and prevalence of necrosis and regeneration, although it
produced lower CK values [29].
There is no doubt that steroids are beneficial for young patients
with DMD and are the standard of care for this disease.
Interestingly, mdx mice do not seem to benefit substantially from
steroid treatment despite a resulting decrease in skeletal muscle
inflammation. We want to point out that treatment effects in
mouse models may be different from the effects one would observe
in patients. The steroid dose we used in our study was slightly
higher than that normally used for children with DMD, and the
steroids were not administered in a single oral dose but rather in
the chow or in slow-release pellets, a difference that might affect
their pharmacodynamic effect and consequently the side effects.
In conclusion, our data strongly demonstrates that chronic
continuous daily administration of GCs to mdx mice significantly
improves strength in the initial stages of the disease, but it also
causes deterioration in muscle and heart function, increases
fibrosis, and contributes to the deterioration of overall activity in
this model. This functional improvement in grip strength is not
correlated with histological decrease in inflammation: GC-treated
mice show a decrease in inflammation both at 100 and 180 days,
without marked improvement in functional measures, suggesting
that decreased inflammation alone is unlikely to improve the
function of dystrophin-deficient muscle. Thus, there is an urgent
need for the development of compounds that provide the anti-
inflammatory potency of standard GCs but with markedly reduced
side effects.
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